{"transactions":[{"id":730079,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-22T23:23:24.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":47784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date."}],"balance_after":47784,"source":{"system":"sec-edgar","filing":"0001193125-26-277933","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000119312526277933/ownership.xml","form_type":"4"}},{"id":876646,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:17:50.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":160000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":44.57,"expiration_date":"2034-07-31","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001193125-26-082268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000119312526082268/ownership.xml","form_type":"4"}},{"id":876645,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:17:50.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":31.42,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-082268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000119312526082268/ownership.xml","form_type":"4"}},{"id":876644,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-27T20:17:50.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92054,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the \"Merger Agreement\"), among Novartis AG (\"Novartis\"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the \"Merger Agreement\"), among Novartis AG (\"Novartis\"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-082268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000119312526082268/ownership.xml","form_type":"4"}},{"id":941847,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-09T22:12:57.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":2374,"price":72.23,"value":171474.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."}],"balance_after":74557,"source":{"system":"sec-edgar","filing":"0001599901-26-000011","document":"wk-form4_1767996774.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000159990126000011/wk-form4_1767996774.xml","form_type":"4"}},{"id":961847,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-19T13:26:08.000Z","date":"2025-12-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":26824,"price":71.87,"value":1927840.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025."}],"balance_after":76931,"source":{"system":"sec-edgar","filing":"0001599901-25-000217","document":"wk-form4_1766150765.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000159990125000217/wk-form4_1766150765.xml","form_type":"4"}},{"id":961846,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-19T13:26:08.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason."}],"balance_after":103755,"source":{"system":"sec-edgar","filing":"0001599901-25-000217","document":"wk-form4_1766150765.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000159990125000217/wk-form4_1766150765.xml","form_type":"4"}},{"id":1074096,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-08-05T21:27:11.000Z","date":"2025-08-04","kind":"sale","planned":true,"acquired":false,"shares":2245,"price":36.21,"value":81291.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on August 1, 2025 and the sale of the resulting shares of common stock on August 4, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.21. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47755,"source":{"system":"sec-edgar","filing":"0001599901-25-000138","document":"wk-form4_1754429224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000159990125000138/wk-form4_1754429224.xml","form_type":"4"}},{"id":1306378,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-09T01:29:15.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in 48 equal installments on each monthly anniversary of the grant date, until it is fully vested on January 6, 2029."}],"balance_after":50000,"derivative":{"exercise_price":31.42,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001599901-25-000025","document":"wk-form4_1736386148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000159990125000025/wk-form4_1736386148.xml","form_type":"4"}},{"id":1306377,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-01-09T01:29:15.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 6, 2025, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001599901-25-000025","document":"wk-form4_1736386148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000159990125000025/wk-form4_1736386148.xml","form_type":"4"}},{"id":1440417,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T13:11:53.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the total number of shares subject to the options shall vest on the first anniversary of August 1, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":160000,"derivative":{"exercise_price":44.57,"expiration_date":"2034-07-31","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001599901-24-000123","document":"wk-form4_1722863507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000159990124000123/wk-form4_1722863507.xml","form_type":"4"}},{"id":1440416,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-08-05T13:11:53.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of August 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001599901-24-000123","document":"wk-form4_1722863507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000159990124000123/wk-form4_1722863507.xml","form_type":"4"}},{"id":1672727,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:42.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83525,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":45.88,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":83525},"source":{"system":"sec-edgar","filing":"0001140361-24-003540","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000114036124003540/form4.xml","form_type":"4"}},{"id":1672726,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-01-24T01:37:42.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":71660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units (\"RSUs\") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-003540","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000114036124003540/form4.xml","form_type":"4"}},{"id":1672725,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-01-24T01:37:42.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company (\"BMS\"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of January 23, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the \"Closing Consideration\") and (B) one contingent value right (a \"CVR\"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the \"Merger Consideration\"), without interest and subject to any withholding taxes."}],"balance_after":71660,"source":{"system":"sec-edgar","filing":"0001140361-24-003540","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000114036124003540/form4.xml","form_type":"4"}},{"id":1810620,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-08-10T20:22:43.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":22297,"price":37,"value":824989.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the one year anniversary of the grant date."}],"balance_after":71660,"source":{"system":"sec-edgar","filing":"0001628280-23-028878","document":"wk-form4_1691698952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000162828023028878/wk-form4_1691698952.xml","form_type":"4"}},{"id":2035203,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Ch. Legal Officer & Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-02T22:34:20.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.87,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-23-006291","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000120919123006291/doc4.xml","form_type":"4"}},{"id":2413004,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CH. LEGAL OFFICER & SEC."}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T00:05:58.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":166250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":166250,"derivative":{"exercise_price":7.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":166250},"source":{"system":"sec-edgar","filing":"0001415889-22-001057","document":"form4-02032022_040246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000141588922001057/form4-02032022_040246.xml","form_type":"4"}},{"id":2972683,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Ch. Legal Officer & Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:57:11.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":161406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":161406,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":161406},"source":{"system":"sec-edgar","filing":"0001209191-20-059523","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000120919120059523/doc4.xml","form_type":"4"}},{"id":2972682,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Ch. Legal Officer & Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:57:11.000Z","date":"2020-09-19","kind":"grant","acquired":true,"shares":252060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on September 8, 2021 and 1/48 of the total number of shares subject to the option vest each month\nthereafter, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable."}],"balance_after":252060,"derivative":{"exercise_price":4.824,"expiration_date":"2030-09-18","underlying":"Common Stock","underlying_shares":252060},"source":{"system":"sec-edgar","filing":"0001209191-20-059523","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564621/000120919120059523/doc4.xml","form_type":"4"}},{"id":3091368,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Restricted Stock Units","published_at":"2020-07-02T16:35:33.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":37083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37083},"source":{"system":"sec-edgar","filing":"0001209191-20-040346","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040346/doc4.xml","form_type":"4"}},{"id":3091367,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T16:35:33.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":96874,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In connection with the Merger, these options were accelerated and canceled without payment."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":96874},"source":{"system":"sec-edgar","filing":"0001209191-20-040346","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040346/doc4.xml","form_type":"4"}},{"id":3091366,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T16:35:33.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."}],"balance_after":0,"derivative":{"exercise_price":12.79,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001209191-20-040346","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040346/doc4.xml","form_type":"4"}},{"id":3091365,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T16:35:33.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":65000,"price":5.21,"value":338650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."}],"balance_after":0,"derivative":{"exercise_price":12.79,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-20-040346","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040346/doc4.xml","form_type":"4"}},{"id":3091364,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Performance Stock Units","published_at":"2020-07-02T16:35:33.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":24375,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24375},"source":{"system":"sec-edgar","filing":"0001209191-20-040346","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040346/doc4.xml","form_type":"4"}},{"id":3091363,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Performance Stock Units","published_at":"2020-07-02T16:35:33.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":48750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the Effective Time, each performance restricted stock unit ( \"Issuer PSU\") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the \"Exchange Ratio\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the Effective Time, each performance restricted stock unit ( \"Issuer PSU\") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the \"Exchange Ratio\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the Effective Time, each performance restricted stock unit ( \"Issuer PSU\") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the \"Exchange Ratio\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":48750},"source":{"system":"sec-edgar","filing":"0001209191-20-040346","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040346/doc4.xml","form_type":"4"}},{"id":3091362,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-07-02T16:35:33.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":12893,"price":18,"value":232074.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the \"Issuer\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Odyssey Merger Sub Inc. (\"Merger Sub\") (the \"Merger Agreement\"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-040346","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040346/doc4.xml","form_type":"4"}},{"id":3231653,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-03-03T18:58:47.000Z","date":"2020-03-02","kind":"tax_withholding","acquired":false,"shares":4327,"price":9.68,"value":41885.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,119 shares acquired under the Issuer's employee stock purchase plan on February 28, 2020."}],"balance_after":49976,"source":{"system":"sec-edgar","filing":"0001209191-20-015665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120015665/doc4.xml","form_type":"4"}},{"id":3246018,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Performance Stock Unit","published_at":"2020-02-26T20:26:39.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":73125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (PSU) represents a contingent right to receive one (1) share of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Any PSUs not yearned on the three (3) year anniversary of the grant date will expire."}],"balance_after":73125,"derivative":{"expiration_date":"2023-02-24","underlying":"Common Stock","underlying_shares":73125},"source":{"system":"sec-edgar","filing":"0001209191-20-013274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120013274/doc4.xml","form_type":"4"}},{"id":3291127,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-04T19:03:23.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2020, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":65000,"derivative":{"exercise_price":12.79,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-20-006663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120006663/doc4.xml","form_type":"4"}},{"id":3291126,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-02-04T19:03:23.000Z","date":"2020-02-03","kind":"tax_withholding","acquired":false,"shares":3544,"price":12.89,"value":45682.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":53184,"source":{"system":"sec-edgar","filing":"0001209191-20-006663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120006663/doc4.xml","form_type":"4"}},{"id":3291125,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-02-04T19:03:23.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\") in consideration of services rendered. The RSUs vest in three equal annual installments subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each vest date."}],"balance_after":56728,"source":{"system":"sec-edgar","filing":"0001209191-20-006663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120006663/doc4.xml","form_type":"4"}},{"id":3611474,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2019-03-05T18:30:35.000Z","date":"2019-03-04","kind":"tax_withholding","acquired":false,"shares":4297,"price":33.42,"value":143605.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":39952,"source":{"system":"sec-edgar","filing":"0001209191-19-016983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119016983/doc4.xml","form_type":"4"}},{"id":3677156,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T17:56:18.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2019, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":75000,"derivative":{"exercise_price":27.1,"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-19-006910","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119006910/doc4.xml","form_type":"4"}},{"id":3677155,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2019-02-04T17:56:18.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\") in consideration of services rendered. The RSUs vest in three equal annual installments on January 31, 2020, January 31, 2021 and January 31, 2022, subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each such date."}],"balance_after":43750,"source":{"system":"sec-edgar","filing":"0001209191-19-006910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119006910/doc4.xml","form_type":"4"}},{"id":3978683,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-30T17:24:36.000Z","date":"2018-03-29","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option vests as follows: 25% of the shares shall vest one year from the Vesting Commencement Date of March 12, 2018, and the remaining shares shall vest ratably over the next 36 months."}],"balance_after":125000,"derivative":{"exercise_price":32.66,"expiration_date":"2028-03-28","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-022235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118022235/doc4.xml","form_type":"4"}},{"id":3978682,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2018-03-30T17:24:36.000Z","date":"2018-03-29","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSU\") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2019, subject to Reporting Person's Continuous Service as of each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Grant of Restricted Stock Units (\"RSU\") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2019, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-18-022235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118022235/doc4.xml","form_type":"4"}},{"id":4071047,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-02-08T19:16:24.000Z","date":"2018-02-08","kind":"sale","acquired":false,"shares":1200,"price":115.7,"value":138840.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.25 - $117.25.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":74537,"source":{"system":"sec-edgar","filing":"0000899866-18-000037","document":"wf-form4_151813537006905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000037/wf-form4_151813537006905.xml","form_type":"4"}},{"id":4071046,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-02-08T19:16:24.000Z","date":"2018-02-08","kind":"sale","acquired":false,"shares":2163,"price":115.7,"value":250259.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $115.20 - $116.20.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":75737,"source":{"system":"sec-edgar","filing":"0000899866-18-000037","document":"wf-form4_151813537006905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000037/wf-form4_151813537006905.xml","form_type":"4"}},{"id":4071045,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-02-08T19:16:24.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 6,500 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary."}],"balance_after":77900,"source":{"system":"sec-edgar","filing":"0000899866-18-000037","document":"wf-form4_151813537006905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000037/wf-form4_151813537006905.xml","form_type":"4"}},{"id":4071044,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-02-08T19:16:24.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":21489,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 21,489 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary."}],"balance_after":71400,"source":{"system":"sec-edgar","filing":"0000899866-18-000037","document":"wf-form4_151813537006905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000037/wf-form4_151813537006905.xml","form_type":"4"}},{"id":4072803,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-02-07T18:35:43.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":1261,"price":117.26,"value":147864.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."}],"balance_after":49911,"source":{"system":"sec-edgar","filing":"0000899866-18-000015","document":"wf-form4_151804652977932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000015/wf-form4_151804652977932.xml","form_type":"4"}},{"id":4415440,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Option to Purchase Common Stock","published_at":"2017-03-01T19:46:21.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":12800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Stock option award under 2004 Incentive Plan.  25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years."}],"balance_after":12800,"derivative":{"exercise_price":131.25,"exercise_date":"2018-02-28","expiration_date":"2027-02-28","underlying":"Common Stock, par value $.0001 per share","underlying_shares":12800},"source":{"system":"sec-edgar","filing":"0000899866-17-000060","document":"wf-form4_148841556728953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000060/wf-form4_148841556728953.xml","form_type":"4"}},{"id":4415439,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:46:21.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Award of Restricted Stock Units under the 2004 Incentive Plan.  25% vests on each anniversary of the grant date."}],"balance_after":51172,"source":{"system":"sec-edgar","filing":"0000899866-17-000060","document":"wf-form4_148841556728953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000060/wf-form4_148841556728953.xml","form_type":"4"}},{"id":4415438,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:46:21.000Z","date":"2017-03-01","kind":"sale","acquired":false,"shares":282,"price":132.5,"value":37365.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":44672,"source":{"system":"sec-edgar","filing":"0000899866-17-000060","document":"wf-form4_148841556728953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000060/wf-form4_148841556728953.xml","form_type":"4"}},{"id":4415437,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:46:21.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":910,"price":131.71,"value":119856.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":44954,"source":{"system":"sec-edgar","filing":"0000899866-17-000060","document":"wf-form4_148841556728953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000060/wf-form4_148841556728953.xml","form_type":"4"}},{"id":4415436,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:46:21.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":612,"price":131.2,"value":80294.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":45864,"source":{"system":"sec-edgar","filing":"0000899866-17-000060","document":"wf-form4_148841556728953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000060/wf-form4_148841556728953.xml","form_type":"4"}},{"id":4458017,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-10T18:05:03.000Z","date":"2017-02-09","kind":"sale","acquired":false,"shares":167,"price":126.84,"value":21182.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":46476,"source":{"system":"sec-edgar","filing":"0000899866-17-000036","document":"wf-form4_148676789017357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000036/wf-form4_148676789017357.xml","form_type":"4"}},{"id":4462475,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-08T16:40:19.000Z","date":"2017-02-07","kind":"sale","acquired":false,"shares":135,"price":128.09,"value":17292.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $128.00 - $128.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":46643,"source":{"system":"sec-edgar","filing":"0000899866-17-000029","document":"wf-form4_148659000596099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000029/wf-form4_148659000596099.xml","form_type":"4"}},{"id":4462474,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-08T16:40:19.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":23,"price":126.38,"value":2906.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":46778,"source":{"system":"sec-edgar","filing":"0000899866-17-000029","document":"wf-form4_148659000596099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000029/wf-form4_148659000596099.xml","form_type":"4"}},{"id":4462473,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-08T16:40:19.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":3380,"price":125.69,"value":424832.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":46801,"source":{"system":"sec-edgar","filing":"0000899866-17-000029","document":"wf-form4_148659000596099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000029/wf-form4_148659000596099.xml","form_type":"4"}},{"id":4524600,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":36233,"kind":"person","name":"Moriarty John B","position":1,"cik":"0001564621","reported_name":"Moriarty John B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2016-12-13T18:24:06.000Z","date":"2016-12-12","kind":"sale","acquired":false,"shares":1044,"price":118.61,"value":123828.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $118.00 - $118.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":50181,"source":{"system":"sec-edgar","filing":"0000899866-16-000391","document":"wf-form4_148167143337012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986616000391/wf-form4_148167143337012.xml","form_type":"4"}}]}